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This is the third and final portion of a re-
port of a projeot designed for the purpose of im-
proving standard methods of detecting contact
allergens.
The first dealt with the theoretical and
technical insufficiencies of the conventional
"predictive" tests (1).
The second presented a compendium of ex-
perimental information on the various agencies
which conduce to the establishment and meas-
urement of human contact sensitization (2).
It is the purpose of this paper to present a
new method of bioassay, hereafter called the
"Maximization Test," and to record the per-
formance of this test with a score of well known
substances.
Principles of Test Design
Arbitrary decisions enter into the formula-
tion of any kind of bioassay; the objectives
can be fulfilled only within stated limits. It will
be well to review the concepts on which the
maximization test is based and to present the
empirical strategies which shaped the specifi-
cations.
This task has to be visualized in terms of
the assumption that practically all substances
are capable of being contact sensitizers for
some persons under some conditions. Even the
blandest substances such as lanolin, a vehicle
for countless preparations, may occasionally
sensitize, though diagnosis is often missed be-
cause of a very low order of suspicion (3). The
sensitizing capabilities of the overwhelming
preponderance of substances are very feeble;
one may almost always fine-comb out of the
literature a ease or two of sensitization to
practically anything which contacts the skin.
No feasible procedure can hope to identify
these allergens.
There is however a class of moderate sensi-
tizers which, though not necessarily danger-
ous, have sufficient allergenic potential to
warrant an alertness for their sensitizing possi-
bilities. Medical examples include neomycin,
benzoeaine, procaine, penicillin, and ammoniated
mercury. Any procedure which purports to de-
tect contact allergens must be capable of iden-
tifying substances in this class. The "maximiza-
tion" test was empirically fashioned to meet
this operational standard. Earlier, so-called pre-
dictive procedures failed to achieve this de-
gree of sensitivity (1).
The objective of the maximization test is to
establish whether specified substances have
oIler genie potentialities and to what degree.
The test is primarily designed to yield al-
lergenicity ratings for individual substances, not
complex mixtures, finished products or formu-
lations. It must be thoroughly understood that
the maximization procedure does not directly
assess safety in use (except when negative). It
does not predict the incidence of sensitization
in a population of users. Fundamentally it
classifies substances according to the sensitiza-
tion capabilities these exhibit under an arbi-
trarily defined set of experimental circum-
stances. When it has been established that a
substance is a weak, moderate or strong sensi-
tizer, the primary business of the test is fin-
ished. Estimates of hazard, the degree of harm
which will occur if the substance is incorporated
in various strengths in various products and
used in specified ways, involves additional con-
siderations which are difficult to establish. In
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TABLE I
Maximization grading
Sensitization Rates Grade Classification
0—2/25 1 Weak
3—7/25 2 Mild
8—13/25 3 Moderate
14—20/25 4 Strong
21—25/25 5 Extreme
any case, such estimates are not an inherent
part of the bioassay. We will return to this
question again.
The general principle is somewhat analogous
to the way in which pharmacologists approach
the problem of assaying toxicity. Substances are
not divided into toxic and non-toxic categories.
This is unsound because all substances are
toxic depending on the kind and amount of
exposure. Some method of measuring 'how
toxic' is required. One means of doing this is
the L.D. 50, the mean dose which kills 50% of
the animals. Despite limitations, this is a pre-
cise measurement which at least offers a stand-
ard means of comparing toxicities. In one re-
cently published scheme, common substances
have been classified into six toxicity grades
based on L.D. 50 values as an aid to prognosis
in cases of poisoning (4).
The conventional attitude toward contact
sensitizers is often naive: the chemical universe
is didactically divided into sensitizers and non-
sensitizers as if these were absolute polarities.
The more appropriate question is "how sensi-
tizing?" With the paradigm of the L.D. 50 in
mind, I sought first to determine an S.D. 50
dose which would sensitize 50% of the subjects.
This aim was completely frustrated by the
exceedingly great difficulty, indeed impossibil-
ity, of inducing sufficiently high sensitization
rates with weak allergens. It was necessary to
be satisfied with a more conservative, less pre-
cise, screening technic. This was a matter of
integrating all the previously acquired experi-
mental information into a scheme which would
most magnify the opportunity for sensitization.
The score attained by a substance under these
maximizing circumstances might then afford a
quantitative means of comparison. Some in-
dulgences had to be tolerated for the sake of
practicality. For instance, although the sensiti-
zation rate is, with qualifications, proportionate
to the number of exposures, five were sufficient
to identify the moderate sensitizers with regu-
larity. Similarly, while accuracy and repro-
ducibility would be better served by using a
large number of subjects, we found it possible
to meet the operational standard with a test
panel of 25 subjects.
A procedure finally emerged whose useful-
ness and limitations were empirically estab-
lished by testing a large number of substances
about which information was available from
many years of actual use. The closeness of fit
of maximization scores and the verdicts of
usage constituted the cardinal test of merit
of the maximization procedure.
From the range of results obtained, a quite
arbitrary scheme of ratings was devised to af-
ford a simple measure for quantitative com-
parisons. Substances were divided into five
classes, numbered one to five, according to
their allergenic potentialities. (Table I). To
each class was assigned a simple English
equivalent, 'weak' to 'extreme', denoting com-
parative potency. It is emphasized that these
ratings are relative and not absolute.
* * *
Specifications of the Maximization Test
The Patch—The patch material is a non-
woven, highly absorbent, cloth, prepared by
Curity under the trade name of Webril. It provod
the most serviceable of many tried including
various paper discs, and woven cloths of cotton,
flannel and wool. Webril is sufficiently bnlky to
maintain a steady force against the skin, some-
what akin to the sponge pressure patch test of
Fernstrdm (5).
Absolute occlusion is essential. Complete seal-
ing prevents loss of the test agent and favors
penetration by providing maximum hydration.
Squares of Webril, 1.5" along the sides, are used
for the induction exposures. These are fastened to
an extremity (forearm or calf) as follows: Two 3"
lengths of 1.5" wide impermeable plastic tape are
overlapped ¼" lengthwise to form a 3.0" x 2.5"
rectangle. The tape is 3 M Blenderm, made by
the Minnesota Mining Company. It has good
sticking powers and is completely impermeable to
water, though it does possess limitations in that
it predisposes more than conventional tapes to
anhidrosis, a forerunner of miliaria in hot
weather. Moreover unlike white cloth-backed
tapes, bacterial multiplication is not restrained.
The Blenderm is centered over the Webril patch.
(Fig. 1). The surrounding area may be sprayed
Fio. 1. Stage I. Construction of inductive patch on forearm. Two overlapping strips of
impermeable plastic tape (3 M Blenderm) have been fastened over the Webril (Curity)
patch.
Fio. 2. Stage II. Perforated plastic tape has been wrapped around the forearm several
times to form an occlusive, thoroughly secured seal.
.Rio. 3. Appearance of induction site after five exposures to 5% SLS just prior to last
appheation of the test material. The lesion isa moderately inflammatory placque covered
with a clean exudate. Tape marks are also evident.
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with tincture of benzoin to enhance adhesion and
reduce irritation. The patch is held in place by en-
circling the extremity several times with Johnson
and Johnson Perforated Band-Aid Clear Tape, 1.5"
wide (Fig. 2). This tape is somewhat more elastic
than Blenderm, is porous and molds better to the
variable diameter of the extremity.
The challenge patches, generally on the lower
back, are also of Webril except that the size is
reduced to 1" squares. These are covered as
above by the Blenderm rectangle. Placed over
this is an identically sized, 2.5" x 3", single piece
of ordinary white adhesive. The back skin is
more mobile than the lower forearm and greater
reinforcement is necessary to maintain complete
occlusion for 48 hours. Bending and turning
tend to deform the skin and to disrupt the
Blenderm strips unless these are reinforced as
above. The area surrounding the patch may be
sprayed with tincture of benzoin from an aerosol
can. Finally the patch is held in place by over-
lapping strips of Johnson and Johnson Per-
forated Clear Plastic tape arranged to form about
a 4.5" square. It is permissible to use the forearm
for challenge testing in which case the patch is
fastened as for induction by wrap-around taping.
No commercially available patch guarantees the
occlusion provided by the above arrangement
which is admittedly more tedious.
During induction, tape reactions of some de-
gree are common, and sometimes extremely trou-
blesome, especially in hot weather. Some com-
fort is afforded if, at the time of changing the
patches, pieces of cotton cloth are placed over
the more irritated areas before being bound
down by the perforated tape.
For induction, a volume of 1.0 ml of the test
material is delivered to the Webril patch via a
plastic syringe, minus the needle. For challenge
0.4 ml is used with the smaller patch.
Preparation of the Test Material for Induc-
tion.—Crystalline substances are vigorously tritu-
rated into U.S.P. white petrolatum. The test agent
is first ground to a fine powder with a mortar and
pestle. Coarseness is to be avoided. It is unnecessary
to bring the agent into solution in a suitable solvent
before adding it to the petrolatum. For non-irritat-
ing solids, the concentration of the test substance is
25% by weight; i.e. 25 grams to 75 grams of petro-
latum. Higher concentrations are to be avoided
since pasty masses form which give lower rates of
sensitization. If the test agent is irritating, as
judged by pilot study, the concentration is the
greatest one which will produce a moderate ery-
thema within 48 hours. Vesiculation, oozing or
erosions signify too great an injury. For example,
2% is adequately irritating for mercuric chloride,
5% for formalin, and 0.2% for a potent irritarzt
like diethylfumarate. A severe dermatitis de-
presses the sensitization rate. Liquids may be
handled a little differently. These are free of the
limitation of becoming less sensitizing after some
maximum concentration. If non-irritating, they
may be used undiluted as for example, extract
of Krameria. If irritating they are diluted in
mineral oil or petrolatum in the highest con-
centration productive of a mild dermatitis in
48 hours, as with crystalline agents.
In practice, most test substances seem to be
solids.
Subjects—A panel of 25 healthy adult sub-
jects is used. Institutional volunteers are ideal
since strict controls can be exerted. Our ex-
perimental population was made up of prisoners
exclusively. It is not practical to work with
children or infants. Although contact sensitivity
to potent allergens can be established in the
aged, it is not known with certainty whether
sensitizability or skin reactivity is fully sustained.
In consequence, the preferred age range is 18 to
50 years.
It is important to note that the maximization
ratings presented in this paper refer to Negroes
who comprised 90% of our experimental sub-
jects. As indicated in the earlier work, inflamma-
tion to irritants and allergens is less readily pro-
duced in pigmented skin (2). This difference in
reactivity is not significant in the case of strong
allergens. With weaker allergens, higher sensitiza-
tion rates are to be expected in white subjects.
The test procedure involves certain discomforts
which may make it injudicious to use women
as test subjects. There is, however, no reason to
suspect an important sex difference in suscepti-
bility. None has been found in guinea pigs
(personal communication of Magnusson).
Induction Procedure .—T he sensitizing patches
are applied to an extremity, either the forearm
or the lower leg in the calf region. The entire
series of patches are applied to exactly the
same site. The procedure has the following basic
structure for non-irritating substances:
1. Deliver 1.0 ml of 5% aqueous sodium lauryl
sulfate (SLS) to a 1.5" square of Webril. Fasten
occlusivcly to extremity for 24 hours. This treat-
ment produces a moderate inflammatory re-
action which promotes sensitization.
2. Apply to the same site a 48 hour occlusive
patch with the test material.
3. Repeat this sequence of alternating 24
hour irritant and 48 hour allergen patches for a
total of five exposures of each. The procedure
therefore consists of five 48 hour exposures,
each one preceded by a 24 hour pre-treatment
with 5% SLS. The inflammation will tend to
increase somewhat with each SLS exposure,
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reaching a maximum by the third or fourth
time. (Fig. 3) The SLS pre-treatments are elim-
inated if at any time the skin becomes too in-
flamed. There should never be ulceration. Some-
times an agent which is non-irritating by pilot
testing in 25% concentration on normal skin
becomes severely so when applied to SLS damaged
skin. This can usually be satisfactorily handled
by omitting further exposures to SLS. The aim is
to keep the skin moderately inflamed during the
exposures. Usually the subjects tolerate the pro-
cedure with little complaint.
A modification in the technic of producing in-
flammation is permissible, and indeed desirable,
which simplifies the procedure. Instead of 24 hour
pre-treatments with sodium lauryl sulfate, the
surfactant may be incorporated into the test
mixture at 5% concentration, provided there is
certainty of chemical compatibility. The pro-
cedure then involves five 48 hour combined
allergen-irritant exposures with one day intervals
of complete rest. However, a chemical reaction
between the allergen and the surfactant may
inactivate one or both, spoiling the test com-
pletely. If there is no way to test compatibility,
doubt should be eliminated by not combining
the two. Incompatibility is however uncommon.
Irritating substances require no pre-treatment
with SLS. These produce their own inflammation.
By pilot testing on the normal skin of ten subjects,
a concentration is selected which produces a brisk
dermatitis in a 24 hour occlusive patch. One day
rest periods are allowed between the five 48 hour
exposures. If the skin becomes too inflamed, the
concentration is appropriately reduced in the final
exposures. Strong allergens are frequently strong
irritants; on the other hand, most irritants are not
allergenic.
A sudden exacerbation or flare on the fourth
or fifth allergen exposure almost certainly in-
dicates the onset of sensitization; the patch is
removed forthwith and not reapplied. The sub-
ject must be challenge-tested nonetheless. When
several allergens are being simultaneously tested
on different extremities, the flare of several sites
does not necessarily indicate separate sensitiza-
tion. Sensitization to a single allergen, if par-
ticularly strong, may cause exacerbation of all
the other sites owing to hematogenous distribu-
tion of allergen and its extravasation into the
inflamed tissues. These are 'id' responses local-
ized to irritated areas where the circulating
antigen is deposited. In routine testing these
'ids' are decidedly uncommon but utterly bewil-
dering if not recognized.
Challenge Test.s.—The "SLS provocative patch
test," described in detail elsewhere, is routinely
employed when appropriate (6). The provocative
test consists of pre-treating the skin occlusively
with 0.4 ml of 10% SLS on a 1.0" Webril square
for one hour. This produces sub-clinical in-
flammation in 48 hours. Non-irritating solids are
routinely tested at 10% in petrolatum; liquids
may be used undiluted if non-irritating. The
qualification for the SLS provocative test is
that the test substance, if solid, should not, in
ten normal subjects, significantly intensify the
mild inflammation of the SLS treated site when
a 10% concentration in petrolatum is applied
occiusively for 48 hours. If it does, but is non-
irritating on the normal skin of ten subjects,
it should be used on unprepared skin. More
irritating solid substances are used on normal
skin at the highest concentration in petrolatum
which produces no inflammation in ten normals.
Similarly, liquids may be used at the highest
non-irritating concentration on normal skin or
on SLS pre-treated skin if non-aggravating.
Irritancy is established by pilot testing of no
less than 10 subjects. One may expect great
individuality in irritatibility. A 1% concentration
is generally a safe concentration with which to
begin range finding. The challenge reaction is
read immediately after removal of the 48 hour
patch and again in another two days. Subjects
are asked to return if reactions develop still
later, an unusual but not rare event. An evident
erythema is the minimum positive response. The
reliability of this response has been verified
histologically, though of course, erythema is
certainly not a specific sign of allergic response.
Marginal erythematous reactions are operated one
week later.
A control patch is necessary for the provocative
test consisting of petrolatum applied for 48 hours
to a site pretreated for one hour with 10%
aqueous sodium lauryl sulfate. The control site
will usually show no reaction, or occasionally a
very mild erythema may be present. The mild
inflammatory reaction induced by SLS is mainly
discernible at the microscopic level. The allergen-
treated site is not regarded as positive unless it
is clearly more inflammatory than the control
site. Patch testing is a simple but nonetheless
difficult technic. It is the weakest and most
fallible part of the procedure. The vagaries of
patch testing have been discussed by Rostenberg
and by myself (6).
One must have enough experience to suspect
false positive reactions which in certain subjects
may take the form of miliaria (heat rash) or
bacterial infection; the latter is not always a
pyoderma due to S. aureus. Strong reactions with
vesiculation, edema and extension beyond the
Webril patch are unequivocally allergic. Mild,
non-eczematous reactions presenting only ery-
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TABLE II
Topical therapeutic and cosmetic agents
Induc-
Substance
tion
tration
(%)*
Challenge
cOncentra-
(%)
Sensiti
zation
rate
Sensi-
tiza-
grade
Soap (Ivory) 10 0.1 0/23 1
Sodiumlaurylsulfate 10 0.1 0/22 1
Petrolatum 25* 10.O** 0/25 1
Lanolin 25* 1O.O** 0/25 1
Tween 80 25* 5.0 0/21 1
Propylene glycol 25* 1O.0** 0/24 1
Crude coal tar 20 5.0 0/25 1
Salicylic acid 20 10.0 0/25 1
Aluminum chloride 25 10.0 0/20 1
Zirconium lactate 25* 10.0 0/22 1
Zirconium sulfate 25* 10.0 1/24 1
Xylocaine® 25* 10.O** 0/25 1
Benadryl® 25* 10.O** 0/25 1
Pyribenzamine® 25* 1O.O** 0/25 1
Resorcinol 15 5.0 0/22 1
Benzene hexacliloride 10 2.5 0/24 1
p-aminobenzoic acid 25 10.0 0/25 1
Methyl ester of p- 25* 1O.0** 1/25 1
aminobenzoic acid
Procaine HCL 25* 1O.0** 6/24 2
Benzocaine® 25* 1O.O** 5/23 2
Butyn sulfate 25* 1O.0** 10/25 3
Nupercaine® 25* 1O.0** 11/24 3
Monobenzyl ether of 25 5.0 23/25 5
hydroquinone
Thephorin® 25* 1O.0** 23/24 5
p-phenylenediamine 10 0.5 24/24 5
* Pre-treatment of
vocative test.
skin with SLS, ** SLS pro-
thema, a manifestation of border line sensitivity,
are impossible to distinguish from irritation ex-
cept by histology. This difficulty may be particu-
larly vexing for there is reason to suspect that
contact allergy-prone individuals have more
"irritable" skin. Concentrations which are non-
irritating on most normal persons may produce
reactions in the genetically predisposed. Careful
pilot testing will ordinarily assure the use of non-
irritating concentrations. The range of responses
of the normal population to irritants is very much
greater than supposed. Marginal responses to chal-
lenge patch tests with materials that are irritating
in higher concentrations should be repeated.
Results of Maximization Testing
There is but one feasible way to demonstrate
whether maximization testing fulfills the objec-
tive of identifying and rating contact allergens.
One must test a substantial list of diverse sub-
stances whose allergenicity is confidently known
through extensive experience. The following re-
sults show a reasonably good correlation with
the individual verdicts of usage.
I. Topical Therapeutic and Cosmetic Agents
(Table II) .—The allergic innocence of soap, so-
dium lauryl sulfate, petrolatum, and aluminum
salts was confirmed by the test. Likewise lanolin
sensitized no subjects. Although Hjorth be-
lieves lanolin sensitization to be not uncom-
mon, the occurrence of such sensitization must
be an exotic happening in relation to its vast
use (7). That this occurs occasionally is beyond
dispute; the maximization test is not sensitive
enough to detect the feeble allergenic potentiality
of such substances. Although Baer et al report a
20% sensitization incidence to 10% crude coal
tar in petrolatum (8), the maximization assay
does not verify this assessment nor indeed is it
the general experience that crude coal tar is such
a common sensitizer. Ten percent crude coal
tar is, in my experience, an irritating concentra-
tion to many subjects. Likewise I consider irri-
tancy to be the likely cause for 5% sensitization
rates reported by Baer et al for salicylic acid and
resorcinol (8). These are present in innumerable
derrnatologic products and have a splendid record
of allergic safety. Both were non-sensitizing by
maximization testing.
These disparities emphasize the great impor-
tance of assuring that non-irritating concentra-
tions be used for challenge. Border-line irritant
and allergic reactions are not distinguishable
clinically.
It cannot be too strongly emphasized that no
sensitization by test does not signify absolute
lack of allergenicity. The correct judgement is
that the capacity for sensitizing is very low.
Some practically never sensitize (pure soap, for
instance), while others like lanolin do so rarely.
These are lumped together for the practical
reason that they do not constitute an allergic
hazard. With pyribenzamine and hexachioro-
phene (9) which are feeble but occasional sen-
sitizers, repetition of the test in different
groups of 25 does not invariably yield no re-
actors, but sometimes one or two. It is for this
reason, that even when there are up to two
reactors per test group, the substance is still
labeled a Grade I sensitizer.
Focusing on the other end of the rating scale,
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we see that certain topical agents frequently
demonstrate themselves to be potent sensi-
tizers. Three of these are assigned a maximum
Grade of V, designated as extreme sensitizers;
p-phenylenediamine (10) (a hair dye and long
known olympic sensitizer much used for experi-
mental sensitization), monobenzyl ether of
hydroquinone (a depigmenting agent and rub-
ber antioxidant, a sometime cause of shoe
dermatitis (11)), and Thephorin® (12). These
are all well-known sensitizers.
How do agents stigmatized by experience as
moderate allergens fare? The 'caine' group of
topical anesthetics provides an interesting ex-
ample for much fear attends their topical use.
The hazard is recognized in innumerable warn-
ings; yet some of these continue in widespread
use. The term 'caine' is an unfortunate appela-
tion since the various members of this group
are not all chemically related. Some are also
immunologically distinct. Baer considered that
the local anesthetics caused more contact sen-
sitization than any other group of topical
therapeutic agents (13). The incidence of pro-
caine sensitivity is thought to be so high by
dentists that is has been considered an occupa-
tional hazard (14). In examining the maximi-
zation scores, procaine and benzocaine turn out
to be Grade II, mild sensitizers, perhaps not
quite so dreadful as commonly imagined. Al-
though dermatologists inveigh lustily against
its use, benzocaine in one to five percent con-
centration occurs in an extraordinary number
of proprietary topical agents. The sales record
does not seem to bear out the baleful judge-
ment of the dermatological establishment, and
neither does maximization testing (Grade II)
Nupercaine®, different from procaine and ben-
zocaine by not possessing a para-amino-benzoic
acid nucleus, is a more potent sensitizer than
procaine, as is butyn sulfate. These are Grade
III, moderate sensitizers. At any rate, all these
'caines' have been stigmatized as sensitizers.
It is particularly significant that none of the
test panel became sensitized to Xylocaine®.
This is not a 'caine' but actually a xylene
derivative. It does not cross-react with procaine
and indeed, it is not clinically regarded as a
sensitizer. Thus, in the group of local anes-
thetics there is an acceptable correlation be-
tween the verdicts of use and bioassay. It
should be noted that p-aminobenzoie acid
itself is not a significant sensitizer though it
may evoke a reaction in subjects sensitized to
some other member of the well publicized
'para' group of aromatic amines which includes
aniline dyes, sulfonamides, local anesthetics
and hair dyes. Mayer, in his classic monograph,
aptly calls substances like p-aminobenzoic acid
'elicitors' (15). They do not sensitize in their
own right but can call forth the allergic re-
sponse in a subject sensitized to some other
member of the cross-reacting spectrum. The
maximization test may have an important
function in distinguishing primary allergens
from 'elicitors'.
Finally, although zirconium salts used as
antiperspirants in stick form are uncommonly
capable of inducing allergic granulomas (18),
very little sensitization occurs from the exten-
sive use of topical solutions and creams. The
maximization rating is appropriately Grade I,
a weak sensitizer. Very few contact sensitizers
are capable of this unique granulomatous sen-
sitization.
* * *
Anti-microbial Agents (Table III) .—A very
sizeable clinical experience may be tapped to
judge the congruence between usage and bio-
assay judgements.
Neomycin, to begin with, is a useful case for
didactic purposes. Its over-the-counter use has
been vigorously condemned (17). Dermatolo-
gists are quite aware of its sensitizing capabili-
ties and some consider it a rather potent con-
tact sensitizer (18). Nonetheless, it is widely
used to advantage. Neomycin is dubbed a
Grade II, mild sensitizer by the maximization
test. This estimate seems consonant with clini-
cal experience.
By contrast, penicillin G and streptomycin,
are rarely used topically for fear of contact
sensitization. This hazard is fully appreciated
(19). Both are Grade IV, strong sensitizers by
bioassay. Experience seems validated and the
prohibition of their topical use apparently
justified. Procaine penicfflin is apparently less
sensitizing than penicillin G.
On the other hand, contact sensitization to a
host of broad spectrum antibiotics, tetracycline,
erythromycin and chioromycetin is virtually
unknown. Polymyxin likewise has no sensitiza-
tion stigma. The maximization scores, all
Grade I, are in strict accordance with this
opinion. Kanamycin, not used topically in
America, is interestingly enough a Grade III
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TABLE III
Antimicrobial agents
Induc-
Agent
tion
con-
cen-
tration
(%).
Challenge
concentra-
tion
(%)**
Sensiti-
zation
rate
Sensi-
tiZa-
tion
grade
Griseofulvin
Amphotericin B
Bacitracin
Achromycin
Erytliromycin
Chioromycetin
Polymyxin B
Sulfathiazole
Sulfanilamide
Hexachlorophene
Bithionol
Phenol
Sodium pentachloro-
phenate
Roccal®
Ceepryn®
Viol orm®
Tetramethyithiuram
disulfide
Procaine penicillin
Neomycin
Kanamycin
Lugol's solution (Io-
dine)
Ammoniated mercury
Penicillin G
Streptomycin
Furacin®
Formalin
Mercuric chloride
Tetrachlorosalicyl-
anilide
* Pre-treatment of skin with SLS, ** SLS pro-
vocative test.
moderate sensitizer. It has chemical affinities to
neomycin and cross-reactions are documented
(20). The maximization verdict of marginal
sensitizing power, Grade I, for the halogenated
phenols, hexachlorophene and bithionol, is con-
cordant with the rarity of contact sensitization,
despite the presence of these bacteriostatic
agents in countless consumer products. On the
other hand, the test does not verify the common
clinical opinion of phenol as a fairly strong
sensitizer. The disagreement here is sharp; no
subject was sensitized. The writer's opinion
is that the clinical judgement needs amending;
phenol reactions are more likely instances of
irritation, or perhaps cross-sensitization to
some other phenolated compound. Actually,
strong corrosive agents such as trichioracetic
acid, zinc salts and others much used as
chemical cauterants are rarely sensitizing,
probably because they denature the proteins
1 with which they combine. One halogenated
1 phenol, pentachiorophenol, sensitized two
1 members of the test panel. On the whole, the
1 common substituted phenols do not, contrary
1 to common opinion, constitute a class of
1 strong allergens.
1 High correlation between usage and maxi-
1 mization testing was found for the quaternary
ammonium germicides, Roccal® and Cee-
1
pryn®. These are Grade I sensitizers, and
1 clinical sensitization is rare. Vioform® en-
1 joys the same agreeable position.
Iodine, mercuric chloride, ammoniated mer-
1 cury and formalin well deserve their reputa-
1 tions as contact sensitizers. Bioassay acknowl-
1 edges this propensity; all are Grade III or IV
2 sensitizers.
Tetrachloro-salicylanilide caused vivid epi-
demics of photosensitivity soon after its in-
corporation in soap (21). Significant numbers
of the victims were contact-sensitive at the
same time and reacted to simple, unirradiated
3 patch tests (22). This is a very strong al-
4 lergen by maximization tests (Grade V).
4 Tetramethyl-thiuram disulfide was incor-
4 porated in a popular brand of soap (Lifebuoy)
4 for several years and was used by millions. It5 was finally dropped because of discoloration
problems. Sensitization was practically un-
known. Nonetheless, it has caused occasional
contact sensitization in the rubber industry
where it is used as an accelerator (23). It is
one of the causal agents to be considered in
rubber and shoe contact allergy (24). On the
record then it is a modest sensitizer. By maxi-
mization testing it is a mild sensitizer (Grade
II).
We come now to a dramatic example of dis-
parity between the verdicts of clinical usage
and maximization testing. No group of agents
has been more strongly stigmatized as con-
tact sensitizers than the sulfonamides. Very
shortly after their introduction for topical
chemotherapy, the literature rang with loud
alarums (25). They were so loudly condemned
that no manufacturer since has dared to fight
25*
25
25*
25*
25*
25*
25*
25*
25*
25*
25*
2
5
25*
25*
25*
25
25*
25*
25*
20
25*
25*
25*
25*
5
2
5
10**
10
10**
10**
10**
10**
10**
10**
1o**
10
10**
1.0
1.0
10.0**
10.o**
10**
10
10**
10**
10**
0.25
10**
10**
10**
10**
1.0
0.05
1.0
1/25
0/23
0/25
0/25
0/21
0/22
0/25
1/25
5/25
0/23
0/24
0/24
2/25
0/24
0/24
0/23
4/25
9/25
7/25
11/24
9/25
13/25
16/24
20/25
14/24
18/25
23/25
22/25
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popular prejudice even with newer and con-
siderably modified derivatives which might be
quite innocent. In the face of this infamous rep-
utation, it is disquieting to find that sul-
fathiazole is a Grade I weak sensitizer while
sulfanilamide, reportedly the worst offender of
the class, is only Grade II. Repetition of the
test did not alter these largely negative find-
ings. Interestingly, there are reports of ex-
tensive topical use in which sensitization was
not encountered (26). This matter warrants
further study, especially since I have obtained
much higher sensitization rates with certain
newer sulfonamides, sulfadimethoxine, for ex-
ample. It is idle to speculate about the cause
of the "failure" of maximization testing in the
case of the older sulfonamides.
Bacitracin sensitized none of the test panel.
Pirilä and Rouhunkoski in Finland found that
each of 101 neomycin-sensitive subjects was
also patch test-positive to bacitracin (27).
Epstein and Wentzel claim to have sensitized
10 of 10 guinea pigs with this antibiotic (28).
They think that patients with sensitivity to
neomycin and bacitracin have become sepa-
rately and coincidentally sensitized to both. The
Finnish observers, on the other hand, conclude
that bacitracin regularly cross-reacts to neo—
mycin. The latter interpretation is radical to
say the least, since bacitracin is a polypeptide
with no chemical relationship whatever to
neomycin. Moreover, it would be extraordi-
nary for a polypeptide to be capable of contact
sensitization. My persuasion from maximiza-
tion testing and examination of the chemistry
is that uncontaminated bacitracin is not a
sensitizer. Moreover, none of the subjects ex-
perimentally sensitized to neomycin cross-
reacted to bacitracin. The resolution of this
kind of dispute is another application for
maximization testing.
Furacin® is considered so strong a topical
sensitizer that its use is generally condemned.
Maximization testing shows it to be a strong,
Grade IV, sensitizer. The question of its con-
tinued topical use will be resumed later.
Industrial Contact ants (Table IV) .—Con-
tact sensitization is an important problem in
the chemical and manufacturing industries.
Schwartz, Tulipan and Birmingham's colossal
volume lists hundreds of sensitizers by in-
dividual industry (32). The availability of so
many substances whose allergic reputation is
Induc- Chal-
tion
concen-
lenge
concen-
Sensiti-
zation
Sensiti-
zation
tration
(%)*
tration
(%)**
rate grade
Benzene
Xylene
Pyridine
Dimethylsuif oxide
(DMSO)
Hexane
Chlornapthalene
Aniline
Mercaptobenzothia-
zole
Nickel sulfate
Chromium trioxide
Chromium sulfate
Cobaltous sulfate
Gold chloride
Turpentine
Butyiglycidyl ether
Beryllium sulfate
2-amino-5-diethyl-
aminotoluene HCI
Potassium dichro-
mate
Phenyl mercuric ni-
trate
Thioglycerol
Diethylenetriamine
Diethylfumarate
n-butylthiomalate
Technical Mala-
thion®
Glyoxal
Krameria (Extract)
Epoxy resin
Hydrazine
* Pre-treatment of skin with SLS, ** SLS pro-
vocative test.
thoroughly established proved an unusual op-
portunity to test very strong and very weak
allergens.
It is illuminating to review the history of
attempts to sensitize humans to nickel. Long
ago Jadassohn and Schaaf repeatedly applied
strong nickel sulfate solutions to normal and
abraded skin but achieved no sensitization
(29). More recently Vandenburg and Epstein,
applying the allergen to skin damaged by
freezing, sensitized 9% of 172 subjects (30). In
Western countries, nickel is a leading sensitizer
401
TABLE IV
Industrial contactants
50
100
50
75
100
25
20
25*
10
3
25
25
2
50
10
5
25*
2
2
50
10
1 .C
5.C
25*
10
25*
25
5
20
25
10
25
25
10
10
10**
2.5
0.5
2.0
2.5
0.005
20
10
1.0
10**
0.25
0.5
5
10
0.2
1.0
10.0**
2.0
10**
15
0.5
0/25
0/24
1/24
0/23
0/25
0/25
7/25
9/24
12/25
13/23
11/23
10/25
16/23
18/25
19/24
18/22
19/25
23/23
24/25
24/24
21/25
25/25
22/25
25/25
24/24
22/22
21/25
23/23
1
1
1
1
1
1
2
3
3
3
3
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
5
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TABLE V
Systemic drugs
Substance
Induc-
tion Con-
centra-
tion (%)
Challenge
Concentra-
tion
(%)**
Sensiti-
zat ion
rate
Sensi-
tiza-
tion
grade
Thiabendazole 25* 10** 0/23 1
Testosterone 25* 10** 0/23 1
Chlortrimeton® 25* 10** 0/25 1
Hydrocortisone 25* 10** 0/25 1
Hydrodiuril® 25* l0 0/24 1
8-methoxypsoralen 25* 10** 0/24 1
Miltown® 25* 10" 0/23 1
Aralen® 25* l0** 9/25 3
Phenergan® 25* 10** 10/25 3
Atabrine® 25* 10** 18/23 4
Chiorpromazine 25* 10** 18/24 4
Neoarsphenamine 10 5 16/24 4
Apresoline® 10* 5Ø** 24/24 5
BAL® 10 2.0 23/23 5
* Pre-treatment
vocative test.
of skin with SLS, ** SLS pro-
in dermatologic practice. This status is verified
by maximization testing which shows nickel to
be a Grade III sensitizer. If nickel were easily
leached out of the alloys which so frequently
contact human skin, in jewelry for example, the
result would be dermatitically devastating! Ros-
tenberg et al's arguments that nickel reactions
are not due to contact sensitization but are un-
usual responses in genetically deviant individuals
are surprising to me (31).
Hexavalent chromium (bichromate) is recog-
nized as a potent contact sensitizer; small
amounts are mainly responsible for cement
dermatitis (33). There is considerable opinion
that trivalent chromium salts do not cross-
react with hexavalent ones. Fregert and
Rorsman have refuted this curious notion by
showing that Cr" salts regularly elicit reac-
tions in Cry' sensitized subjects (34). I
concur and have gone one step farther by
showing Cr" salts to be not only elicitors but
potent sensitizers as well. Both chromium
trioxide and chromium sulfate are Grade III
sensitizers.
Among metals, cobalt sensitization is al-
most as well known as nickel and chromium
(35). Haxthausen was the first to sensitize
humans experimentally (36). It is a moderate
Grade III sensitizer by maximization test. It
was, of course, expected that turpentine (37),
epoxy resin (Epon 127, Shell Oil Corp.) (38),
krameria (39) and thioglycerol (40) would be
rather strong allergens, and so they turned out
to be. It is worthy of note that the common
organic solvents are rarely sensitizers. This
was well borne out by maximization testing of
xylene, hexane, pyridine, dimethylsuif oxide
and benzene.
Aniline is one of a group of agents re-
knowned for their cross-reactivities, the aro-
matic amines (15). Nonetheless it does not
seem to be a strong primary sensitizer in its
own right. This was borne out by bioassay
which accorded it Grade II status. Mercapto-
benzothiazole, an accelerator in rubber and an
occasional cause of shoe dermatitis (41), was
appropriately scored as a Grade II, mild sen-
sitizer.
Gold is always fascinating. Sensitizations
to it are uncommon (42). The maximization
findings were most interesting in view of a
recent case report of a unique papular reaction
to gold by Shelley and Epstein (43). The
healed induction sites where gold chioride had
been repeatedly applied commonly evolved into
persistent nodular placques or clustered pap-
ules. The sensitization rate by challenge was
quite high (Grade IV). It is apparent from
maximization testing that gold salt is a poten-
tially strong sensitizer; the rarity of this oc-
currence clinically is obviously due to the in-
ertness of this noble metal. It would be as
troublesome as nickel if it were as readily
solubilized by skin secretions. In addition to
causing granulomatous reactions, beryllium is
known to be a potent contact sensitizer (44).
Maximization testing confirms this (Grade
IV). Buckley reported unusual lichen planus-
like contact sensitizations to a color developer,
2-amino-5-diethylarnine toluene HCI (45). By
maximization testing, this agent is indeed
quite a potent sensitizer (Grade IV) though
the reactions were always of the usual eczema-
tous type. Hydrazine, a useful chemical but
fiercely sensitizing (46) was found to be an
extreme sensitizer by maximization testing.
Finally, technical Malathion, an organo-
phosphorus cholinesterase inhibiting insecticide
turned out to be a powerful sensitizer (Grade
V). This interesting result will be discussed
later.
Drugs (Table V) .—As the work progressed,
it became increasingly apparent that those
very drugs which have acquired a reputation
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for frequently causing allergic reactions when
taken by mouth or after injection, were likely
to be strong sensitizers by topical applica-
tion. The capacities for inducing drug and con-
tact allergies paralleled each other. Penicfflin,
streptomycin and gold salts are clear examples.
For a number of reasons, drug and contact
allergy of the skin belong to quite distinctive
categories. An important distinction is that pa-
tients with dermatitis medicamentosa do not
react to patch tests, the sine qua non of con-
tact allergy. However, the type of clinical al-
lergy that a given agent can induce is depend-
ent not so much on its chemical properties as
on the route by which it is given (10). Its
allergenic capabilities will be expressed dif-
ferently in different tissues.
The prospect of using contact sensitization
as a marker of general allergenicity was suffi-
ciently intriguing to encourage testing a
variety of drugs even though these are ordi-
narily not topically applied. The results (Table
V) strongly bear out the impression of paral-
lelism. It appears that the contact sensitiza-
tion system affords a means of estimating the
general allergenic capability of a drug. To con-
sider some examples: The hydrazines tend to
be strong allergens and various derivatives
have been extensively utilized to sensitize
guinea pigs. Apresoline®, a congener used in
hypertension, was found by Mayer et alto be a
strong sensitizer in guinea pigs (47). It is a
Grade V, extreme sensitizer by maximization
test. Though allergic reactions are not a frequent
accompaniment of its use, possibly because of
low doses, the lupus erythcmatosus-like syndrome
induced by Apresolinc may be an allergic ex-
pression.
BAL (2, 3-dimercaptopropanol), indicated
in certain types of metal poisoning, has such
restricted use and is given in such short
courses that its allergic potentialities cannot
adequately be assessed. It is always used
warily. The result of maximization testing sug-
gests that the hazard might be considerable:
BAL is a Grade V, extreme sensitizer. It is
interesting that even when applied to normal
skin, Sulzberger and his co-workers sensitized
20% of 88 subjects (48).
The extensive use of antimalarial drugs
provides, by contrast, a large experience forjudging the incidence of allergic reactions.
For chloroquine (Aralen), skin reactions may
occur in as high as 20% and up to 35% in
some series (49). As always one must be ex-
ceedingly careful not to inculpate "allergy" as
the sole mechanism of drug reactions, but
there can be little doubt that this is frequently
responsible for certain reactions associated with
chioroquine therapy. By maximization test it
is a Grade III, moderate sensitizer. The history
of Atabrine suggests that it is a more potent
sensitizer than Aralen (50). This was borne
out in the maximization rating of Grade IV.
If for no other reason, the use of penicillin
for the treatment of syphilis must be appre-
ciated because of the extraordinary panorama
of allergic and toxic reactions which compli-
cated treatment by arsenicals like neoarsphen-
amine. Sulzberger first demonstrated the potent
contact sensitizing properties of arsphenamine
in guinea pigs (51). The maximization test is
certainly confirmatory. Neoarsphenainine is a
Grade V, extreme sensitizer.
The extensive use of chlorpromazine affords
another opportunity to estimate the dimen-
sions of adverse drug reactions. Some kind of
rash, assuredly not all allergic, is estimated to
occur in 6 to 13 percent of patients (52). By
maximization assay, chlorpromazine is a
Grade IV strong sensitizer. This result indi-
cates that large doses for long periods might be
associated with a distressing amount of drug
sensitivity. It is well known that medical per-
sonnel dispensing the drug may acquire con-
tact sensitization (53).
Another phenothiazine derivative, prome-
thazine (Phenergan), to which drug hyper-
sensitivity undoubtedly occurs was accorded the
status of a grade III sensitizer. The remaining
drugs in Table V, none of which are thought to
cause allergic reactions commonly were not found
to be significant sensitizers by maximizatinn as-
say.
Reproducibility of Marimization Testing
The validation of a procedure which claims
both to identify and grade contact allergens is
contingent upon its repeatability. To this end,
a score of different substances were tested on
three separate occasions. Agents from each of
the five classes of potency, from borderline to
extreme, were included.
The results displayed in Table VI permit the
following judgments: Reproducibility is ex-
tremely high at both ends of the scale; upon
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TABLE VI
Reproducibility of "maximization" grades
p-aminobenzoic
acid
Hexachiorophene
Tetramethyithi-
uramdisulfide
Benzocaine®
Chioroquine di-
phosphate
Penicillin G
Ammoniated mer-
cury
Monobenzyl ether
of hydroqui-
none
Apresoline®
Tetrachiorosali-
cylanilide
Induc-
tion
concen-
tration
(%y.
25* 0/23 0/24 0/24 1 1 1
* SLS provocative test.
0/24 1/25 0/23 1 1 1
4/22 1/23 1/25 2 1 1
5/24 3/24 5/22 2 2 2
9/24 6/2511/23 3 2 3
16/23 12/23 13/25 4 3 3
13/2511/2415/25 3 3 4
22/2225/2524/25 5 5 5
repetition, very weak and very strong allergens
are likely to be assigned the same rating.
There is greater variability in the borderline
group especially with substances which are
recognized as occasional sensitizers.
In the mid-zone of moderate allergenicity,
the reproducibility is not as firm as at the
poles. The shift, however, is rarely more than
one grade class, from III to II perhaps or III
to IV. The number of subjects sensitized may
be somewhat variable reflecting mainly individ-
ual differences in sensitizability. Chance alone
will occasionally lead to the selection of test
panels which include an unusual number of
hyper- or hypo-sensitizable individuals.
In sum, powerful allergens are invariably
productive of large reactions; feeble ones typi-
cally silent, and mild and moderate allergens
variably expressive. Obviously both accuracy
and reproducibility are susceptible of improve-
ment by using larger numbers of test subjects.
Hazard& of Maximization Testing
No novel agent should be applied to human
skin unless some preliminary toxicologic in-
formation is available, even though the risk of
serious harm is very small. Nonetheless the
maximization test specifies prolonged, magnified
exposure of deliberately damaged, and there-
fore more permeable, skin to high concentra-
tions of the test substance. A perusal of the
agents reported herein shows that a great
variety of substances may be safely tested
which would be strongly toxic or even lethal
if sufficient amounts were administered orally
or parenterally; viz, heavy metals, solvents,
cholinesterase inhibitors, phenols, certain bac-
teriostats, etc. It is not the obviously toxic
chemicals which are likely to confound the ex-
perimenter, but potent pharmacodynamic
agents, small quantities of which may have pro-
found effects on autonomic, cardiac or central
nervous system functions. For example, when
I unwittingly used 25% Apresoline on SLS
treated skin, the subjects uniformly presented
the same symptoms which an excessively high
oral dose would have produced: tachycardia,
headache, nausea, vertigo and altered emotions.
With this exception, no serious systemic or
cutaneous effects have been produced in any
of thousands of volunteers. Often to save
time and money, four agents were tested simul-
taneously, one on each extremity. Generalized
dermatitis has never occurred even though it
was not exceptional for a subject to acquire
three or four independent sensitizations.
Dermatitis was almost exclusively confined to
the patch site except when the occlusive dress-
ing separated and the allergen thereby con-
taminated other regions. Eosinophilia is a
silent, regular accompaniment of multiple
sensitizations, usually in the range of five to
twenty percent of the white cells.
The only residuum is the state of sensitivity
itself. Obviously the subject can develop a
dermatitis if skin contact occurs subsequently.
This seems a small risk. The ingestion or in-
jection of agents to which subjects are contact
sensitive may produce a variety of reactions,
mainly cutaneous and rarely of any serious-
ness. Anaphylaxis is unknown. I have discussed
this question in detail in connection with hypo-
sensitizing poison ivy sensitive subjects by the
administration of Rhus antigens (54).
Interpretation of Maximization Ratings
The maximization procedure classifies sub-
stances according to their allergenic poten-
tials under greatly exaggerated circumstances
of exposure which bear no resemblance to
normal use. The ratings are comparative, not
Substance
Sensitization rates
test no.
1 2 3
Grades
test no.
123
25
25
25*
25*
25*
25
25
5
5
25/25 24/24
24/24 22/23
555525/2524/25
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absolute. The test is not directly predictive in
the sense of earlier procedures (1). It is on the
score of interpretation that the maximiza-
tion test is likely to be misunderstood and mis-
used.
It would be disingenuous to pretend that
maximization scores have no application with
regard to the formation of judgements of
cutaneous safety. They may be decidedly help-
ful. Some examples will make clear the issues
that arise in the interpretation of the test re-
sults.
It seems almost certain that substances
which are classified as Grade I, weak sen-
sitizers by maximization assay are safe to use
under any conditions. This result signifies ex-
ceedingly low allergenic potential. Although I
am chary of the term 'predictive', such a result
does indeed forecast that the incidence of sen-
sitizers will probably be negligible. It is the
best possible result for the producer and if it
does not guarantee absolute safety in every
case (the sulfonamide disparity) it is a very
strong indication of allergic innocuousness.
More troublesome is the case of Grade IV and
Grade V allergens. What disposition is to be
made of these? Should the substance be
banished forthwith? This would be a vulgar
misinterpretation, an irrational persistence of
the naive habit of designating substances as
either sensitizers or non-sensitizers. Practically
any substance may be a sensitizer, and even
potent ones need not be excluded from usage.
Returning to the paradigm of L.D. 50
toxicity ratings, it is obvious that highly toxic
substances are not immediately excluded from
drug exploitation, provided of course, that the
desired pharmacologic action can be obtained
by using non-toxic amounts. To judge other-
wise would be to remove some of the most
important drugs from the therapeutic reper-
toire. There is always the need to balance the
risks against the rewards. The interpretation of
maximization ratings is analogous. Grade V,
extreme sensitizers, are not automatically
banned from use. Many factors will need to be
considered: concentration in the product, fre-
quency of use, transient or continuous con-
tact, extensiveness of contact, normal or ab-
normal skin, physical state, benefit anticipated,
etc. There will inevitably be disagreements
concerning the weighting of these various con-
tingencies to determine if the risk is justified.
The potential users may see the matter in a
light different from the specialists. Baer speak-
ing of cosmetics says that the "occurrence of
any sensitization in a series of 100 or 200
guinea pigs (!) should make one shy away
from a product which has the expressed pur-
pose only of improving the appearance of the
consumer." (55) The millions of women who
dye their hair with p-phenylenediamine, an
extreme Grade V sensitizer, would doubtless
take exception to Baer's estimate of the im-
portance of appearance. Manufacturer and
user alike appreciate the sensitizing danger of
this powerful allergen. Warnings are printed
on the label; pre-use patch tests are often
required. No agent has been more vividly
stigmatized as a sensitizer which, incidentally,
includes contact allergy to other frequently en-
countered members of the cross-reacting 'para'
group. The fact is that the actual sensitizing
rate is very much less than might be supposed,
even though p-phenylenediamine is so power-
ful that a single application of 1.0 ml of 10%
solution to the forearm will sensitize about 80%
of the population. However, considerably less
than one percent of the women who dye their
hair develop contact allergy. Perhaps this can
be explained by the fact that the dye is mainly
applied to the hair, and not to the skin of
the scalp. Moreover, scalp skin is far less
reactive to contact allergens than ordinary
glabrous skin. With care, some sensitized
women may and do continue to dye their
hair; they are willing to take the risk because
they consider the cosmetic effects of p-phenyl-
enediamine matchless.
The same evaluative process applies to
monobenzyl ether of hydroquinone, a Grade
V sensitizer, used cosmetically (by prescrip-.
tion) for lightening abnormally pigmented
skin. The clinical incidence of sensitization is
of the order of 10 to 20% and the agent is
used daily over a period of several months.
The unsightliness of skin discoloration seems to
justify its continued use despite the strong
risk of sensitization.
Ammoniated mercury still has its adherents
as a topical germicide despite its known sensi-
tizing capacity.
Gold and nickel salts are extreme Grade V
sensitizers. Considering its versatility, nickel
will continue in widespread use because it is
usually encountered as an alloy from which the
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metal is solubilized with difficulty. Metallic
gold is essentially inert.
Malathion is a particularly instructive ex-
ample of the possibility of faulty interpreta-
tion of maximization ratings. Technical Mala-
thion is a Grade V, extreme sensitizer. Tons of
this effective organophosphorous insecticide
have been used, apparently without difficulty,
since its introduction about ten years ago.
Milby and Epstein clouded the record by re-
porting a few cases of sensitization in agricul-
tural workers (56). They issued severe warn-
ings. How could so potent a sensitizer be used
in prodigious quantities, especially as a spray
or dust to which skin contact is unavoidable,
with scarcely a whisper of allergic trouble? It
has even been extensively used as a human
delousing agent without ever revealing its al-
lergenic capacities. Perhaps there are many un-
diagnosed cases as Milby and Epstein suggest?
I judge it more likely that the transient condi-
tions of contact with concentrations that are
usually not higher than 1% have saved this
product from disuse. Suppose the maximiza-
tion test had been performed before the prod-
uct was released for sale? Transpose these
circumstances to the present anxious scene of
hypersensitivity to the adverse effects of drugs
and chemicals. Would this important class of
insecticides have been developed? In a study
which Goltz and I shall report later, it devel-
oped that the actual sensitizer was not
Malathion, but diethylfumarate, a reactant in
its manufacture, present in about 3% of the
technical product. By further purification the
concentration was reduced to less than 0.25%
and the allergenicity of technical Malathion
thereby diminished. The important lesson
learned here is that minor ingredients may
sometimes play a decisive role; problems of
this kind are resolvable by the maximization
procedure. Above all there is no justification
for peremptorily dismissing the use of a chem-
ical because it is rated as a Grade V sensitizer
by maximization testing. Potentiality need not
become actuality. Moreover, no test has the
force or merit of a substantial history of safe
use.
The problem of proper interpretation of
maximization ratings is so important that I
risk laboring the issue unduly. Much instruc-
tion is to be gained from the case of Furacin®,
a Grade IV strong sensitizer by maximization
assay. Most dermatologists apparently never
use this preparation; this model of probity is
scrupulously ignored by surgeons and general
practitioners. In a total of 2,573 reported cases,
the sensitization rate was 2% among all spe-
cialities (57). The highest incidence, 6%, was
recorded by a dermatologic group. The great
difficulties of forming true estimates of sensi-
tizing potentiality by usage history is illus-
trated by the failure of some experienced ob-
servers to come across a single case of contact
sensitization (59, 60). These disagreements
stem from a multitude of variables: The expe-
rience of the observer, duration and frequency
of contact, kind of skin lesion treated, etc.
What probably enables Furacin® to be sold de-
spite its allergenic capability, is not the ob-
durateness of non-dermatologists but the fact
that the use concentration is 0.2%, whereas
25% was used in maximization testing.
Thephorin® provides a contrasting experience.
It is an antihistaminic which is of ques-
tionable topical therapeutic value. Its low clinical
effectiveness has to be assessed against its status
as a Grade V extreme sensitizer by maximiza-
tion testing. Moreover, the use concentration
is comparatively high, 5%. Dermatologists be-
gan to warn about sensitization shortly after
its introduction. Shelmire recorded a 1.3%
sensitization incidence; (61) Layman et al had
a corroborative experience (62). Both groups
thought this a low incidence and not disquiet-
ing. But 28% of Ellis and Bundick's patients
became sensitized, mainly because the chronic
dermatoses were treated for longer periods,
averaging almost two months.'2 Similarly
D'Avanzo's patients used the agent for months
and 16% became sensitized (63). In this case,
the sum of clinical experience is unfavorable
for the continued use of Thephorin.® Retrospec-
tively, I believe that this would have been the
interpretation of the maximization rating. This
judgement would be likely because: (1) the
product is to be used on abnormal skin, (2) it
may be applied several times daily for months
and (3) 5% is too high a concentration.
For much the same reasons, the topical use
of penicillin does not seem justified, even
though the remedy is effective. Accurate pre-
diction is nonetheless almost impossible. The
information is never enough to encompass all
the known and unknown variables of use. It is
most interesting that at least one highly repu-
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table pharmaceutical firm (Lilly) continues to
market penicillin cream. The manufacturer has
received only four complaints of sensitization
since 1960! The maximization scores are at
least obtained under rigidly defined conditions,
and along with other information relevant to
intended use should be helpful in making an in-
formed guess about the magnitude of the risk.
Modification of the Basic
Maximization Procedure
When the maximization rating is high, I
tentatively suggest that testing with a lower,
non-maximizing concentration may provide
helpful data for determination of practical
usefulness of the substance. The testing pro-
cedure is exactly the same; the only change is
the reduced concentration. This may be called
the 'reduced maximization test.' From an ex-
perience which is still too limited, some sug-
gestions as to choice of concentration may be
offered. If the agent is to have intimate, pro-
longed contact with skin in a form which re-
leases the active principle (liquids, ointments,
etc.), the test concentration might be twice
that of normal use. If none of the 25 test
subjects become sensitized, one may cau-
tiously undertake test marketing. The effect of
concentration on sensitization rate has been
presented in the previous paper from which
some intelligence relevant to our present pur-
pose may be extracted (2). In the case of
Thephorin®, a 1% concentration, one-fifth that
of use, sensitized about a quarter of the test
group. To use 5% would be utterly unaccept-
able.
For Furacin® there were no sensitizations
at the use concentration of 0.2%, and only
three out of twenty-five at 1.0%. Nonethe-
less, the record clearly shows that Furacin®
does sensitize subjects at use concentrations
despite the negativity of the reduced maximi-
zation test. I would interpret this result in the
same way that the manufacturer has done
without this type of bioassay. Some patients
are likely to be sensitized, but not enough to
prohibit distribution. A negative 'reduced
maximization' test means only that the sensi-
tization frequency will probably be tolerable,
not that none will occur. By repeated applica-
tions, residual quantities may accumulate to
result ultimately in quite higher concentra-
tions.
With penicillin G and streptomycin, 1% con-
centrations, which approximate use, sensitized
respectively 4 and 8 subjects of 22 tested. The
risk is too high.
At use concentrations of 1%, neomycin sen-
sitized no one of the test panel. Patients of
course do become sensitized to 1% neomycin.
At first view, it is alarming that neomycin is now
the most common contact allergen in Finland, 700
cases having been seen in this country of accurate
case reporting (64). But we are elsewhere in-
formed that more than 2,000,000 units have
been sold (27). My judgement is different than
that of certain others (17) who are outraged by
the prospect of neomycin being incorporated
in over-the-counter formulations such as deo-
dorants. In fact, two such preparations con-
taining less than 0.2% neomycin are now
widely sold in the United States, and the
sensitization rate is very low. By maximization
testing neomycin is only a mild, Grade II, sen-
sitizer. By the reduced test 1% use concentra-
tions are non-sensitizing. At one-fifth this con-
centration, I believe neomycin to be safe for
over-the-counter use. Shehahdeh and Kligman
did not encounter any sensitization in their
experimental study of neomycin-containing
deodorants (65).
In the ease of certain solid materials in
which the potential allergen is not truly avail-
able for skin contact (plastics, clothing, woods,
household articles, etc.) I would provision-
ally propose that the product is safe if use
concentrations are non-sensitizing in the 're-
duced maximization test.' Individual judgements
will obviously be required for every substance.
When uncertainty cannot be resolved the only
recourse is usage testing particularly under
exaggerated conditions of exposure
SUMMARY
1. A new procedure, the maximization test,
for identifying and rating contact sensitizors
by human bioassay is presented.
2. Substances are classified according to their
allergenic capabilities after five 48 hour ex-
posures of high concentrations to inflamed skin.
3. The maximization ratings of many diverse
substances, including cosmetics, drugs, indus-
trial contactants, etc. have been presented.
4. Uses of the test include:
a. Judgement of the contact sensitizing haz-
ard of new chemicals.
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b. Discrimination between primary allergens
and cross-reacting 'elicitors.'
c. A model for evaluating the potentiality of
orally or parenterally administered agents to
cause allergic drug reactions.
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